You are here: Industry Insights > Emergent BioSolutions

News List

Emergent BioSolutions and Vaxart partner on oral coronavirus vaccine pharmaceutical-technology
March 20, 2020
Emergent BioSolutions has agreed to provide molecule-to-market contract development and manufacturing (CDMO) services for Vaxart’s oral vaccine candidate against Covid-19 coronavirus infection.
Emergent, Vaxart Ink Coronavirus Pact contractpharma
March 19, 2020
Sign development and manufacturing agreement for experimental oral vaccine candidate.
Emergent BioSolutions Initiates Development of Plasma-Derived Candidates Coronavirus americanpharmaceuticalreview
March 18, 2020
Emergent BioSolutions has initiated development of two product candidates for the treatment and prevention of coronavirus disease (COVID-19).
Emergent BioSolutions, Novavax Enter COVID-19 Pact contractpharma
March 11, 2020
Emergent BioSolutions has entered into a COVID-19 agreement with Novavax. It will collaborate with Novavax, utilizing its molecule-to-market contract development and manufacturing (CDMO) services to support bringing ...
Emergent Strengthens Clinical Ops contractpharma
March 06, 2020
Emergent BioSolutions has partnered with Axiom Real-Time Metrics, a provider of unified eClinical solutions and services. Emergent has selected Axion’s Fusion eClinical suite as its global eClinical suite.
mergent BioSolutions and Valneva’s Zika vaccine turns up positive early-phase data fiercepharma
December 04, 2018
A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results, laying the groundwork for a potential technology transfer to Emergent.
Emergent BioSolutions Acquires Maker of Narcan Nasal Spray americanpharmaceuticalreview
August 31, 2018
Emergent BioSolutions has entered into an agreement to acquire Adapt Pharma and its flagship product Narcan (naloxone HCl) Nasal Spray, the first and only needle-free formulation of naloxone approved by the U.S. Food and Drug Administration (FDA) and Heal
Emergent BioSolutions to acquire Adapt Pharma for up to $735 million firstwordpharma
August 29, 2018
Emergent BioSolutions on Tuesday announced that it entered into an agreement to acquire Adapt Pharma for up to $735 million, gaining the latter's Narcan (naloxone) nasal spray. Daniel Abdun-Nabi......
Emergent BioSolutions to acquire PaxVax for $270m pharmaceutical-technology
August 14, 2018
US-based life sciences company Emergent BioSolutions has signed an agreement to purchase specialty vaccines developer PaxVax for $270m under a cash-based consideration.
Under new collaboration, Valneva and Emergent BioSolutions agree to co-develop Zika shot fiercepharma
August 08, 2017
Valneva and Emergent BioSolutions have signed a deal that could be worth about €50 million to develop a Zika vaccine.

Previous page 1 2 3 Next page